Roche launches DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research

  • Multiplexed assays for simultaneously detecting several biomarkers in a single sample address the growing need to obtain more information from limited tissue samples
  • New test kit is an addition to line of DISCOVERY ULTRA instruments, uniquely designed for the research community
  • Researchers can now investigate more cancer biomarkers on a single tissue slide, paving the way for a better understanding of cancer biology and future advances in personalised healthcare

Continue reading

Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)

  • About 235,000 people in the US will be diagnosed with lung cancer in 2021, with non-small cell lung cancer (NSCLC) accounting for 84 percent of all lung cancers1
  • ALK — anaplastic lymphoma kinase — is an important biomarker found in NSCLC, and targeted therapies have been shown to dramatically improve progression-free survival compared to the previous standard of care2,3,4
  • The VENTANA ALK (D5F3) CDx Assay5 is now FDA approved as a companion diagnostic in four targeted treatments, providing more options to lung cancer patients

Continue reading